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ABSTRACT
Introduction: The prevalence of prescription
opioid use disorders in the US has increased
markedly in parallel with increases in opioid
prescribing. Whilst an increase in opioid pre-
scribing has also occurred in the UK, it remains
unknown if there have been concurrent
increases in opioid use disorders. The aim of this
study was to examine national trends in the
prevalence and incidence of physician-diag-
nosed opioid use disorders in the UK.
Methods: In a retrospective electronic health
care database analysis using data from the UK
Clinical Practice Research Datalink (CPRD), we
identified persons receiving a first opioid pre-
scription between January 1, 2008 and Decem-
ber 31, 2012. Persons with an opioid use
disorder were identified by Read codes assigned
by patients’ physicians within 6 months fol-
lowing an opioid prescription. We calculated
prevalence and incidence rates by dividing the
analysis population by the total number of
patients exposed (prevalence) or the total
patient-years of exposure (incidence) using the
‘exact’ Clopper–Pearson Binomial method.
Results: Our analysis included 714,699 per-
son-years of prescription opioid exposure. The
5-year period prevalence of opioid use disorders
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was 4.61 (95% CI 4.28–4.96) per 10,000 indi-
viduals, or 0.05%. The incidence rate of opioid
use disorders was of 6.51 (95% CI 5.93–7.13)
patients per 10,000 patient-years exposed.
When examined by study year, there was no
clear suggestion of a changing trend over time.
When stratified by opioid drug, trends in the
incidence rate during the study were either
stable (i.e., codeine and tramadol), increasing
(i.e., morphine) or decreasing (i.e.,
dihydrocodeine).
Conclusions: Our study demonstrates that
despite the marked increase in overall opioid
prescribing in the UK in the past decade, there
has not been an increase in the incidence of
physician-diagnosed opioid use disorders.
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INTRODUCTION
The increase in the prescribing of opioid anal-
gesics for the management of pain has been
paralleled by increases in adverse outcomes
associated with misuse and abuse, particularly
in the United States [1]. Despite increased pre-
scribing of opioid analgesics in Europe [2], few
studies have sought to investigate the extent of
this relationship [3]. In a recent review of pre-
scription opioid use disorders by Vowles et al.
[4], of the 38 studies included, only two were
from Europe. Because the US is not comparable
to most European countries in terms of the
health care system and prescription practices
[5], the strength of the relationship between
prescription opioid use and subsequent risk of
misuse and abuse seen in the US should not be
assumed to be generalizable beyond North
America.
Similar to the US, the UK has seen a marked
increase in opioid prescribing in the past dec-
ade, especially of the stronger opioids [6]. In
contrast to the US, however, there is limited
information on the relationship between pre-
scription opioid use and the development of
opioid use disorders in the UK [4, 5]. As such,
using data from the UK Clinical Practice
Research Datalink (CPRD), the largest database
of anonymized, longitudinal primary care
records including approximately 4.4 million
active patients, we aimed to describe the char-
acteristics of patients with a diagnosis of pre-
scription opioid use disorders and investigate
the 5-year cumulative prevalence and trends in
incidence rates of prescription opioid use dis-
orders between 2008 and 2012. Additionally, we
sought to examine the prevalence and inci-
dence of opioid use disorders stratified by the
different opioids available in the UK.
METHODS
CPRD Database
This study was conducted using data from the
UK CPRD database [7, 8]. In brief, CPRD is a
computerized medical records database con-
sisting of approximately 14 million patients, 4.4
million of which are active patients, from 674
primary care practices throughout the UK
which have recorded anonymized data on
clinical events, referrals to specialist and sec-
ondary care clinics, prescriptions issued in pri-
mary care and lifestyle information. The CPRD
population has been shown to be representative
of the UK population with regard to age, sex,
and geographical distribution [9]. The validity
of the diagnoses recorded in CPRD have
repeatedly been demonstrated in previous
studies [7, 10–12]. The present study uses the
following variables recorded in UK routine
general practice and which are recorded and
available for public-benefiting medical research
from CPRD [13]: anonymized patient identifi-
cation number, age, sex, smoking status, mental
health status, history of alcohol and substance
abuse, and prescription medication information
including specific opioid drug, dispensing date,
pack size, number of packs, and prescription
opioid use disorder medical codes.
This article is based on previously conducted
studies, and does not involve any new studies of
human subjects performed by any of the
authors. Our study protocol was approved by
the Independent Scientific Advisory Committee
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(ISAC) for Medicines and Healthcare Products
Regulatory Agency (MHRA) database research
(ISAC Protocol No.: 14_033R). For all observa-
tional research undertaken using anonymized
CPRD data, ethical approval is granted by the
National Research Ethics Service Committee
(NRES).
Definitions of Problematic Opioid Use
Disorders and Opioid Exposure Duration
A list of medical codes (Read codes) specific for
problematic opioid use disorders was created
prior to study initiation. Read codes provide a
hierarchical clinical coding system used in pri-
mary care in the UK for the purpose of report-
ing, research, decision-making, and to allow
data to be shared reliably between different
computer systems. Following processing and
quality checking, these codes are then added to
the CPRD database.
For this study, an opioid use disorder was
identified by Read codes assigned by patients’
physicians. Read codes identified as indicative
of an opioid use disorder are provided in
Table 1. Cases were included in this study if
they were ascribed an opioid use disorder Read
code within 6 months following an opioid pre-
scription. If a patient was ascribed an opioid use
disorder Read code but did not receive an opioid
prescription in the previous 6 months, then
they did not contribute to this study so as to
reduce the likelihood of including potential
cases resulting from illicit opioid use.
The prescription opioids available in the UK,
and included in this study, categorized by opi-
oid strength, were: codeine, dihydrocodeine,
metazinol, tramadol (weak opioids) and
buprenorphine, diamorphine, dipipanone, fen-
tanyl, hydromorphone, methadone, morphine,
oxycodone, papaveretum, pentazocine, pethi-
dine, and tapentadol (strong opioids).
Duration of opioid exposure (calculated in
days) was estimated based on each prescription
date and the quantity of opioid prescribed, as
recorded in the CPRD database. Long-term
opioid use was defined as a patient having C3
consecutive opioid prescriptions within any 6--
month period during the duration of the study.
Study Population
Persons receiving a first opioid prescription
between January 1, 2008 and December 31, 2012
were eligible for inclusion in these analyses
(n= 1,613,465) (Fig. 1). We excluded patients
who during the study period received an opioid
prescription used for the purpose of substitution
therapy (i.e., patients prescribed methadone
powder or solution formulation, naltrexone, or
buprenorphine oral or sublingual tablets of
doses[1–\8 mg; n = 4021) (Fig. 1). We also
excludedpatients (n = 59,137)who receivedafirst
opioid prescription B6 months prior to the end of
the study (i.e., December 31, 2012) to ensure suf-
ficient follow-up for all persons. Following all
exclusions, 1,550,307 patients were eligible for
these analyses, 715 of which were identified as
havingbeendiagnosedwithanopioidusedisorder
between January 1, 2008 and December 31, 2012.
Of these 715 patients, hereon termed ‘diagnosed
patients’, we then identified a subgroup of ‘‘true’’
‘incident cases’, that is—patientswhodeveloped an
opioid use disorder during the study andwho had
an available healthcare record C6 months prior to
the start of the studywith no evidence of a history
of opioid use disorders (n= 465).
Statistical Analysis
Descriptive characteristics were summarized for:
(1) the total population prescribed opioids who
did not develop an opioid use disorder
(n = 1,549,592), (2) all diagnosed patients
(n = 715) and (3) incident cases (n = 465) using
means with SDs, medians with interquartile
ranges (IQR), or frequencies.
We calculated the 5-year period prevalence
for diagnosed patients by dividing the total
number of patients identified during the study
(i.e., n = 715) by the total number of patients
prescribed an opioid (i.e., n = 1,550,307). We
also calculated the 5-year period prevalence
stratified by opioid drug using the correspond-
ing number of exposed patients as the denom-
inator. For ease of comparison with other
studies, prevalence was expressed as the number
of diagnosed patients per 10,000 patients
exposed.
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The 5-year incidence rate of opioid use dis-
orders, for all opioid drugs combined, was cal-
culated for incident cases by dividing the total
number of incident cases (i.e., n = 465) by the
related total number of years of exposure to
prescription opioids specific to incident cases
(i.e., n = 714,699 person-years), expressed as the
number of patients per 10,000 patient-years
exposed. For the denominator, any time gaps in
opioid prescriptions were subtracted from the
number of patient-days exposed and expressed
in patient-years. We additionally repeated the
incidence rate calculation for diagnosed patients
(i.e., n = 715) since all patients were assigned a
Table 1 Read codes used to identify opioid use disorders, CPRD: 2008–2012
Read codes Description
E255. Nondependent opioid abuse
E2550 Nondependent opioid abuse, unspeciﬁed
E2551 Nondependent opioid abuse, continuous
E2552 Nondependent opioid abuse, episodic
E255z Nondependent opioid abuse NOS
E248. Combined opioid with other drug dependence
E2480 Combined opioid with other drug dependence, unspeciﬁed
E2481 Combined opioid with other drug dependence, continuous
E2482 Combined opioid with other drug dependence, episodic
E2483 Combined opioid with other drug dependence in remission
E248z Combined opioid with other drug dependence NOS
E240. Opioid type drug dependence
E2400 Unspeciﬁed opioid dependence
E2401 Continuous opioid dependence
E2402 Episodic opioid dependence
E240z Opioid drug dependence NOS (disorder)
Eu11. [X] Mental and behavioral disorders due to use of opioids
Eu110 [X] Mental and behavioral disorders due to use of opioids: acute intoxication
Eu111 [X] Mental and behavioral disorders due to use of opioids: harmful use
Eu112 [X] Mental and behavioral disorders due to use of opioids: dependence syndrome
Eu113 [X] Mental and behavioral disorders due to use of opioids: withdrawal state
Eu114 [X] Mental and behavioral disorders due to use of opioids: withdrawal state with delirium
Eu115 [X] Mental and behavioral disorders due to use of opioids: psychotic disorder
Eu116 [X] Mental and behavioral disorders due to use of opioids: amnesic syndrome
Eu117 [X] Mental and behavioral disorders due to use of opioids: residual and late-onset psychotic disorder
Eu11y [X] Mental and behavioral disorders due to use of opioids: other mental and behavioral disorders
Eu11z [X] Mental and behavioral disorders due to use of opioids: unspeciﬁed mental and behavioral disorder
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‘new/first’ opioid use disorder code during the
study irrespective of a previous history of opioid
use disorders; the denominator for this calcu-
lation was the total number of patient-years
exposed for all patients (i.e., n = 729,556 per-
son-years). In further analyses, we calculated
incidence rates stratified by study year (i.e.,
n = 5 years) and opioid drug (i.e., n = 16) for
diagnosed patients as one group to maximize
study power. Consistent with the ISAC policy
for MHRA database research using CPRD data
[14], we do not present results for specific opioid
drugs with B5 patients diagnosed with an opi-
oid use disorder. Consequently, we did not
calculate incidence rates and 95% confidence
intervals (CIs) to determine trends for
buprenorphine, oxycodone, fentanyl,
metazinol, diamorphine, dipipanone, hydro-
morphone, methadone, papaveretum, penta-
zocine, pethidine, and tapentadol. An
individual’s contribution to patient-years of
exposure (calculated in days and expressed in
years) ceased at the date of diagnosis of an
opioid use disorder, December 31, 2012, the
date of death or the date the participant left the
general practice and no longer contributed data
to CPRD, whichever came first. Estimates for
incidence and prevalence, and their corre-
sponding 95% CIs, were calculated using the
‘exact’ Clopper–Pearson Binomial method.
To examine prescription opioid use in fur-
ther detail, we also described: (1) the median
duration from first opioid prescription to being
diagnosed with an opioid use disorder, (2) the
Fig. 1 Flow diagram of persons prescribed opioids, diagnosed opioid use disorder patients, and incident cases, CPRD:
2008–2012
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most frequently prescribed opioid drugs at first
prescription, (3) the opioid drugs which were
most frequently prescribed in the 6-months
prior to a diagnosis of an opioid use disorder, (4)
concomitant prescription of benzodiazepines,
and (5) long-term prescription opioid use.
Finally, we described the frequency of use of the
prescription opioid use disorder diagnostic
codes. Data were expressed using means with
SDs, medians with interquartile ranges (IQR) or
frequencies.
All analyses were conducted using SAS 9.3
(SAS Institute Inc., Cary, NC, USA). Microsoft
Excel was used in the production of Fig. 2.
RESULTS
Study Population
From January 1, 2008 to December 31, 2012, a
total of 1,550,307 individuals received at least
one opioid prescription and had a mean dura-
tion of opioid exposure of 0.47 years, culmi-
nating in 729,556 person-years of opioid
exposure during the 5-year study. Of these, 715
individuals were identified as having an opioid
use disorder (diagnosed patients), 465 of which
were identified as incident cases. Compared to
individuals who received an opioid prescription
but who did not develop an opioid use disorder,
diagnosed patients were more likely to be
younger, male and to have a history of smoking
and alcohol- and substance-abuse disorders. The
baseline characteristics of incident cases were not
dissimilar to diagnosed patients as one group
(Table 2), except for the percentage of men and
the percentage of ‘other substance abuse (in-
cluding alcohol)’, both of which were lower
among incident cases.
Prevalence
The 5-year period prevalence of opioid use dis-
orders among diagnosed patients was 4.61 (95%
CI 4.28–4.96) per 10,000 individuals prescribed
an opioid, or 0.05%. The prevalence of opioid
use disorders was highest among men and those
aged 25–34 years and lowest among women and
those age 55 years or older (Table 3). When
stratified by opioid drug, the 5-year period
prevalence (per 10,000 patients exposed)
among diagnosed patients was highest for oxy-
codone (14.29; 95% CI 10.06–19.69) followed
Fig. 2 Trends in prescription opioid use disorders, UK:
2008–2012. Data for all opioids combined is displayed for
incident cases only (i.e., n = 465) whereas, to maximize
study power due to small numbers, all other data is
displayed for diagnosed patients as one group (i.e.,
n = 715). Data source for opioid prescriptions dispensed
is available from the Health and Social Care Information
Centre [19]
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by fentanyl (8.26; 95% CI 5.49–11.93),
buprenorphine (7.98; 95% CI 5.80–10.71),
morphine (6.94; 95% CI 5.37–8.83),
dihydrocodeine (6.76; 95% CI 5.95–7.64), tra-
madol (4.32; 95% CI 3.69–5.03), and codeine
(2.56; 95% CI 2.29–2.87).
Table 2 Characteristics of persons prescribed opioids, diagnosed opioid use disorder patients, and incident cases, CPRD:
2008–2012
Patients without an opioid use
disorder (n5 1,549,592)
Diagnosed
patients
(n5 715)
Incident cases
(n5 465)
Age at ﬁrst opioid prescription, years
Mean (SD) 53.8 (19.9) 38.6 (12.6) 39.2 (13.8)
Sex, n (%)
Male 635 888 (41.0) 401 (56.1) 233 (50.1)
Female 913 679 (59.0) 314 (43.9) 232 (49.9)
Unknown 25 (\0.1) 0 (0.0) 0 (0.0)
Smoking status, n (%)
Current smoker 799 115 (51.6) 522 (73.0) 333 (71.6)
Previous smoker 497 273 (32.1) 118 (16.5) 92 (19.8)
Never smoker 105 592 (6.8) 14 (2.0) 11 (2.4)
Unknown 147 612 (9.5) 61 (8.5) 29 (6.2)
Previous substance and alcohol abuse, n (%)
Alcohol 49 695 (3.2) 118 (16.5) 69 (14.8)
Other substances (including alcohol) 63 590 (4.1) 307 (42.9) 137 (29.5)
Mental health diagnoses, n (%)a
All mental health disordersb 288 343 (18.6) 472 (66.0) 346 (74.4)
Mood affective disorders 149 888 (9.7) 203 (28.4) 153 (32.9)
Anxiety (neurotic, stress-related and somatoform
disorders)
110 590 (7.1) 189 (26.4) 132 (28.4)
Behavioral syndromes associated with
physiological disturbances and physical factors
20 586 (1.3) 56 (7.8) 44 (9.5)
Schizophrenia, schizotypal and delusional
disorders
5 196 (0.3) 19 (2.7) 12 (2.6)
Behavioral and emotional disorders (onset
usually occurring in childhood/adolescence)
2 083 (0.1) 5 (0.7) 5 (1.1)
a Patients can contribute to multiple categories
b All mental health disorders are comprised of: mood affective disorders; anxiety (neurotic, stress-related and somatoform
disorders); behavioral syndromes associated with physiological disturbances and physical factors; schizophrenia, schizotypal,
and delusional disorders; and behavioral and emotional disorders (onset usually occurring in childhood/adolescence)
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Incidence and Trends in Incidence
A total of 465 patients were identified as incident
cases, equating to an incidence rate of 6.51 (95%
CI 5.93–7.13) patients per 10,000 patient-years
exposed during the 5-year study duration.
When examined by study year, there was no
clear evidence of a changing trend over time
(Fig. 2). If all diagnosed patients were considered
as incident cases, the 5-year incidence rate as one
group would be 9.80 (95% CI 9.10–10.55) per
10,000 patient-years exposed. Similar to the
findings for prevalence, the incidence rate of
opioid use disorders, for all diagnosed patients,
was highest among men and those aged 25–-
34 years and lowest among women and those
age 55 years or older (Table 3). When examined
by study year for diagnosed patients as one group,
there was a suggestion of a declining trend in
the incidence of opioid use disorders over time
[2.60 (95% CI 2.23–3.02) per 10,000 patient--
years exposed in 2008 vs. 2.01 (95% CI
1.66–2.42) per 10,000 patient-years exposed in
2012]. As shown in Fig. 2, when stratified by
opioid drug, trends in the incidence rate during
the study were either stable (i.e., codeine and
tramadol), increasing (i.e., morphine) or
decreasing (i.e., dihydrocodeine).
Prescription Patterns
The median duration from first opioid pre-
scription to being diagnosed with an opioid use
disorder was 0.6 (IQR 0.2–1.9) years for
Table 3 5-year period prevalence and incidence rates of physician-diagnosed opioid use disorders in CPRD: 2008–2012
Prevalence [per 10,000 patients
exposed (95% CI)]a
Incidence [per 10,000 patient-years
exposed (95% CI)]b
Overall 4.61 (4.28, 4.96) 9.80 (9.10, 10.55)
Age group at index
\18 years – –
18–24 years 7.65 (5.98, 9.63) 66.82 (52.32, 84.07)
25–34 years 13.82 (12.14, 15.65) 68.02 (59.81, 77.03)
35–44 years 8.68 (7.52, 9.96) 24.92 (21.60, 28.59)
45–54 years 4.23 (3.46, 5.12) 8.99 (7.35, 10.88)
55–64 years 2.22 (1.68, 2.87) 3.64 (2.76, 4.72)
65–74 years 0.93 (0.59, 1.41) 1.40 (0.88, 2.12)
75–84 years – –
C85 years – –
Sex
Male 6.30 (5.70, 6.95) 14.72 (13.31, 16.23)
Female 3.44 (3.07, 3.84) 6.87 (6.13, 7.67)
All results are for the diagnosed patients i.e., n = 715
a Numerator: number of diagnosed patients during study period, denominator: total number of patients with a prescription
opioid during study period
b Nnumerator: number of incident cases during study period, denominator: years of exposure to prescription opioids during
the study period speciﬁc to incident cases i.e., 714,699 person-years. Total years of exposure to prescription opioids was
calculated in days but reported in whole years
– Robust prevalence and incidence rates, and their corresponding 95% CIs, could not be estimated due to too few cases
(i.e.,\5 cases)
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diagnosed patients and 1.1 (IQR 0.3–2.5) years for
incident cases. The most frequently first pre-
scribed opioid drug was codeine (40.6%) fol-
lowed by dihydrocodeine (32.0%), tramadol
(15.9%), buprenorphine (4.5%), morphine
(4.3%), oxycodone (2.5%), and fentanyl (1.5%).
Consistent with this, the opioid drug which was
most frequently prescribed in the 6 months
prior to a diagnosis of an opioid use disorder
was codeine (43.4%) followed by dihy-
drocodeine (35.8%), tramadol (23.2%), mor-
phine (9.2%), buprenorphine (6.2%),
oxycodone (5.2%), and fentanyl (3.9%). Among
diagnosed patients, a total of 185 (25.9%) were
concomitantly prescribed benzodiazepines and
593 (82.9%) were long-term prescription opioid
users. Among patients without a diagnosis of an
opioid use disorder, 37.8% were identified as
being long-term prescription opioid users.
Opioid Use Disorder Diagnostic Coding
The most frequently ascribed prescription opi-
oid use disorder diagnosis codes during the
study were Eu11 (Mental and behavioral disor-
ders due to use of opioids) (68.7%) and E240
(opioid type dependence) (31.3%).
DISCUSSION
In this large population-based cohort study of
prescription opioid users followed for up to
5 years, we found that the prevalence of opioid
use disorders was low at 0.05% and that there
was no obvious change in the incidence of
newly diagnosed opioid use disorders over the
duration of the study. These findings challenge
the long-standing belief that increases in pre-
scribing of opioids necessitates an increase in
the incidence of problematic opioid use disor-
ders. Our findings also demonstrate that it is the
most commonly first-prescribed opioids, and
not necessarily the more potent opioids, which
are most frequently associated with an opioid
use disorder in the 6 months leading up to
diagnosis of an opioid use disorder.
As far as we are aware, this is the first
nationally representative medical records data-
base study which has sought to investigate the
association between opioid use and risk of sub-
sequent opioid use disorders in the UK. A recent
systematic review of rates of opioid misuse,
abuse, and addiction in chronic pain included a
total of 38 studies conducted mostly in the
primary care setting or pain clinics [4]. Across
most of the calculations, rates of misuse aver-
aged between 21% and 29% (range 95% CI
13%–38%). Of note, the majority of the inclu-
ded studies were not database studies and the
definitions used for misuse were not consistent
across studies. Furthermore, out of the 38
included studies, only two were from Europe
(UK and Denmark), and neither of these studies
included rates for misuse or abuse; only one of
the 38 studies included an estimate of opioid
abuse. A study using UK death data from the
Office for National Statistics has shown an
increasing trend in the number of deaths
attributable to opioids from 2001 to 2011 [15].
However, the results in this study were expres-
sed as absolute number of deaths and did not
account for increases in opioid prescribing over
the same duration. Furthermore, using mortal-
ity data as a proxy for rates of misuse/abuse is
problematic given that many other factors other
than misuse/abuse are known to influence risk
of opioid overdose and death, e.g., opioid dose,
co-prescription with benzodiazepines, time to
administration of an opioid antagonist (i.e.,
naloxone) and response time by emergency
services. A recent study has shown that the
prevalence of past-year misuse/abuse of pre-
scription opioids in Great Britain was 6.2% [16].
The high prevalence of opioid misuse/abuse
found in that study should however be inter-
preted with caution since the participants were
not drawn from a representative nationwide
database but were purposely pre-selected for
problematic use, i.e., they were aged 12–-
49 years, likely to use tobacco and marijuana,
and were recruited from needle exchanges,
homeless shelters, and parks.
In analyses stratified by opioid drug, we found
that the relation between opioid use disorders
and prescriptions of codeine and tramadol
remained stable, whereas therewas an increasing
trend for morphine and a decreasing trend rela-
ted to dihydrocodeine. In a previous study
examining a cohort of new opioid users who
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started treatment with weak opioids (i.e.,
codeine, tramadol, and dextropropoxyphene),
Skurtveit et al. [17] found that 0.08% of patients
went on to develop prescription patterns
indicative of an opioid use disorder. This is con-
sistent with our observation for morphine
which, despite being highlighted as being asso-
ciated with an increasing incidence during the
study,was 0.05%. Skurtveit et al. didnot examine
associations with more potent opioids or mor-
phine, which limits direct comparison with our
findings [17]. We were not able to examine for
trends in opioiduse disorders for buprenorphine,
oxycodone, fentanyl, metazinol, diamorphine,
dipipanone, hydromorphone, methadone,
papaveretum, pentazocine, pethidine, and
tapentadol due to too fewcases. This is important
because whilst our findings suggest that there is
unlikely to be an abuse problem with these
specific opioids at this time, it is not to say that
this will not change in the future. This highlights
the importance for ongoing surveillance of this
important public health issue.
Important strengths of our study include use
of a large representative population database
with up to 5 years of follow-up data and diag-
nosis of opioid use disorders by family physi-
cians. Additionally, use of a publicly available
medical records database, inclusion of an
in-depth statistical analysis strategy, and inclu-
sion of a participant flow diagram, means that
our findings can be replicated and repeated in
future analyses to determine trends in opioid
use disorders over extended durations of time.
There are a number of limitations of our
study which warrant discussion. First, whilst a
number of validation studies have demon-
strated the high validity of the diagnoses codes
recorded in CPRD, reporting strong measures of
sensitivity and specificity [7, 10–12], this has
not been undertaken for the codes related to
problematic opioid use disorders. Secondly,
data on medications given during hospitaliza-
tion, medications provided in specialist care,
and medications provided by a hospital fol-
lowing patient discharge are not recorded in
patients’ medical records. The likely impact of
this will have been an underestimation of drug
use and, potentially, an underestimation of the
extent of opioid use disorders. Nevertheless,
under the assumption that these factors did not
change during the study period, an examina-
tion of annual incidence rates does allow an
accurate estimation of changes in trends over
time even if the absolute number of patients is
not estimated with precision. Thirdly, although
we excluded patients who received an opioid
prescription used for the purpose of substitution
therapy, some of the opioid use disorder cases in
our study may have received a diagnosis of an
opioid use disorder based on illicit opioid use.
This would, however, have led rather to an
overestimation of prevalence and incidence.
Finally, the possibility of significant under-di-
agnosis by patient’s physicians does mean that
future research using alternative data sources is
needed, such as the research being conducted
by the RADARs group in the US who recently
examined prescription opioid misuse and abuse
using multiple data sources in a complimentary
analysis approach e.g., drug-diversion investi-
gations, poison centers and substance-abuse
treatment centers [18].
CONCLUSIONS
In conclusion, despite the marked increase in
overall opioid prescribing in the UK in the past
decade, especially of the stronger opioids, this
has not lead to an increase in the incidence of
diagnosed opioid use disorders. Given the
potential for under-reporting of prescription
opioid use disorders in CPRD, and the likely
important influence that differing prescribing
patterns and health care systems might play in
determining the development of opioid use
disorders, future longitudinal studies using dif-
ferent data sources across Europe are needed to
further our understanding of this important
public health issue.
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